北京英诺特生物技术股份有限公司 2025年第三季度报告

Group 1 - The company and its board guarantee the authenticity, accuracy, and completeness of the quarterly report, assuming legal responsibility for any false records or misleading statements [2][3][6] - The company has recently obtained four new product qualifications, enhancing its product variety and market competitiveness [7][8] - The company plans to hold a Q3 performance briefing on November 10, 2025, to discuss financial results and address investor questions [9][10][11] Group 2 - The company has made adjustments to its core technical personnel, with Ding Zhi no longer recognized as a core technical staff member, while Bai Ting has been newly recognized [15][17][20] - The adjustment of core technical personnel is part of normal structural changes and will not adversely affect the company's research and development capabilities [16][21][23] - The company emphasizes its commitment to research and development, planning to increase investment and optimize talent cultivation and incentive mechanisms [22][23]